Q32 Bio (QTTB) Competitors $3.43 -0.07 (-2.00%) (As of 12/17/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends QTTB vs. NKTX, CKPT, SCPH, ZURA, CDTX, VTYX, TCRX, MCRB, NBTX, and FTLFShould you be buying Q32 Bio stock or one of its competitors? The main competitors of Q32 Bio include Nkarta (NKTX), Checkpoint Therapeutics (CKPT), scPharmaceuticals (SCPH), Zura Bio (ZURA), Cidara Therapeutics (CDTX), Ventyx Biosciences (VTYX), TScan Therapeutics (TCRX), Seres Therapeutics (MCRB), Nanobiotix (NBTX), and FitLife Brands (FTLF). These companies are all part of the "pharmaceutical products" industry. Q32 Bio vs. Nkarta Checkpoint Therapeutics scPharmaceuticals Zura Bio Cidara Therapeutics Ventyx Biosciences TScan Therapeutics Seres Therapeutics Nanobiotix FitLife Brands Nkarta (NASDAQ:NKTX) and Q32 Bio (NASDAQ:QTTB) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their profitability, institutional ownership, valuation, risk, analyst recommendations, media sentiment, earnings, community ranking and dividends. Do analysts recommend NKTX or QTTB? Nkarta presently has a consensus price target of $15.00, suggesting a potential upside of 560.79%. Q32 Bio has a consensus price target of $29.86, suggesting a potential upside of 770.47%. Given Q32 Bio's higher probable upside, analysts clearly believe Q32 Bio is more favorable than Nkarta.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Nkarta 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 2 Strong Buy rating(s) 3.29Q32 Bio 0 Sell rating(s) 4 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.50 Does the media prefer NKTX or QTTB? In the previous week, Q32 Bio had 33 more articles in the media than Nkarta. MarketBeat recorded 34 mentions for Q32 Bio and 1 mentions for Nkarta. Nkarta's average media sentiment score of 0.15 beat Q32 Bio's score of -0.04 indicating that Nkarta is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Nkarta 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Q32 Bio 2 Very Positive mention(s) 6 Positive mention(s) 8 Neutral mention(s) 7 Negative mention(s) 0 Very Negative mention(s) Neutral Do insiders & institutionals have more ownership in NKTX or QTTB? 80.5% of Nkarta shares are held by institutional investors. Comparatively, 31.3% of Q32 Bio shares are held by institutional investors. 8.7% of Nkarta shares are held by company insiders. Comparatively, 16.1% of Q32 Bio shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term. Which has stronger valuation & earnings, NKTX or QTTB? Q32 Bio has lower revenue, but higher earnings than Nkarta. Nkarta is trading at a lower price-to-earnings ratio than Q32 Bio, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNkartaN/AN/A-$117.50M-$1.88-1.21Q32 Bio-$6.65M-6.28-$112.96M-$14.25-0.24 Is NKTX or QTTB more profitable? Nkarta's return on equity of -27.13% beat Q32 Bio's return on equity.Company Net Margins Return on Equity Return on Assets NkartaN/A -27.13% -21.67% Q32 Bio N/A -146.18%-54.49% Which has more risk and volatility, NKTX or QTTB? Nkarta has a beta of 0.82, suggesting that its stock price is 18% less volatile than the S&P 500. Comparatively, Q32 Bio has a beta of -0.46, suggesting that its stock price is 146% less volatile than the S&P 500. Does the MarketBeat Community prefer NKTX or QTTB? Nkarta received 48 more outperform votes than Q32 Bio when rated by MarketBeat users. Likewise, 76.92% of users gave Nkarta an outperform vote while only 75.00% of users gave Q32 Bio an outperform vote. CompanyUnderperformOutperformNkartaOutperform Votes6076.92% Underperform Votes1823.08% Q32 BioOutperform Votes1275.00% Underperform Votes425.00% SummaryNkarta beats Q32 Bio on 12 of the 17 factors compared between the two stocks. Ad Brownstone ResearchDo this Before Elon’s Reveal on January 22ndElon’s newest tech could pay you an extra $30,000 a year — while you sleep. It’s smaller than a quarter but designed to power a $9 trillion AI revolution. And I’ve identified a little-known supplier Elon is depending on to make it all happen.I urge you to watch this video now. Get Q32 Bio News Delivered to You Automatically Sign up to receive the latest news and ratings for QTTB and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart QTTB vs. The Competition Export to ExcelMetricQ32 BioPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$41.78M$6.86B$5.17B$9.32BDividend YieldN/A3.06%4.78%4.06%P/E Ratio-0.2410.75127.7717.55Price / Sales-6.28285.811,261.39139.05Price / CashN/A56.6541.0437.95Price / Book0.155.394.894.92Net Income-$112.96M$151.81M$119.40M$225.78M7 Day Performance-85.95%-5.54%14.54%-1.47%1 Month Performance-89.59%0.33%17.43%5.36%1 Year PerformanceN/A16.04%35.31%22.71% Q32 Bio Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)QTTBQ32 Bio2.8765 of 5 stars$3.43-2.0%$29.86+770.5%N/A$42.63M$-6,651,000.00-0.2439High Trading VolumeNKTXNkarta3.2368 of 5 stars$2.34flat$15.00+541.0%-29.1%$165.13MN/A-1.24140CKPTCheckpoint Therapeutics3.7535 of 5 stars$3.37-8.2%$10.33+206.6%+11.9%$164.56M$100,000.00-1.8310Analyst ForecastOptions VolumeGap DownHigh Trading VolumeSCPHscPharmaceuticals3.7458 of 5 stars$3.28+2.8%$15.00+357.3%-43.2%$164.13M$13.59M-1.6830Gap UpZURAZura Bio3.3086 of 5 stars$2.50+9.6%$15.80+532.0%-45.2%$163.23MN/A0.003Gap UpCDTXCidara Therapeutics3.7808 of 5 stars$23.00+0.5%$32.20+40.0%+59.4%$162.15M$63.90M-0.9090Short Interest ↑VTYXVentyx Biosciences3.2199 of 5 stars$2.28flat$10.00+338.6%+5.3%$161.22MN/A-0.9773News CoverageTCRXTScan Therapeutics2.796 of 5 stars$3.00+5.3%$11.25+275.0%-40.0%$160.11M$21.05M-2.69100MCRBSeres Therapeutics3.7062 of 5 stars$0.92+5.0%$5.08+451.0%-11.3%$157.51M$126.33M-4.04233NBTXNanobiotix2.2977 of 5 stars$3.34+0.3%$12.00+259.3%-43.3%$157.42M$36.22M0.00100News CoverageGap UpFTLFFitLife Brands3.3343 of 5 stars$33.75-0.7%$40.00+18.5%+51.2%$155.18M$62.76M19.8220Positive News Related Companies and Tools Related Companies Nkarta Competitors Checkpoint Therapeutics Competitors scPharmaceuticals Competitors Zura Bio Competitors Cidara Therapeutics Competitors Ventyx Biosciences Competitors TScan Therapeutics Competitors Seres Therapeutics Competitors Nanobiotix Competitors FitLife Brands Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:QTTB) was last updated on 12/18/2024 by MarketBeat.com Staff From Our PartnersTrump’s Secret Manhattan ProjectOn January 20, a whole new Manhattan Project is set to begin: Trump’s Manhattan Project. Folks, I just s...Banyan Hill Publishing | SponsoredHow this >10-cent coin is going to outperform Bitcoin Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredDo this Before Elon’s Reveal on January 22ndElon’s newest tech could pay you an extra $30,000 a year — while you sleep. It’s smaller than a quarter but...Brownstone Research | SponsoredSeeing is believing… Today, I want to share all the details with you… and show you how to leverage this incredible wealth-building ...Porter & Company | SponsoredUncover the Top Gold Stock of the Bull MarketGold Stocks Are Surging—Is West Red Lake Gold Mines Your Next Profit Play?Huge Alerts | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowIt’s here. This is the moment we’ve been waiting for. The next 3-6 months in crypto will be absolutely life...Crypto Swap Profits | SponsoredPlease don’t take this warning lightly…Something huge is about to hit the stock market. Wall St. legend Louis Navellier calls it: "The most signif...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Q32 Bio Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Q32 Bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
